Silas Inman

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.

Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.

Acting 3 months ahead of schedule, the FDA approved ponatinib for the treatment of patients with all phases of CML and Ph+ALL that is resistant or intolerant to prior TKIs.

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

The FDA announced plans to strengthen the supply of 2 scarce cancer drugs: methotrexate and Doxil.

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

The FDA granted orphan drug approval to Erwinaze (asparaginase Erwinia chrysanthemi) to treat acute lymphoblastic leukemia (ALL).

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

ODAC unanimously recommended accelerated approval for brentuximab vedotin (Adcetris) in 2 types of lymphoma.

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasis–free survival with Xgeva versus placebo.

Prostate cancer metastases, or cancer growing outside the prostate glands, can occur in any organ but is seen most frequently in the bone.

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer